IL-6R blockade with tocilizumab disrupts pericyte– and tumor cell–driven IL-6/STAT3 signaling, enhancing docetaxel efficacy in ER+ breast cancer
Source Nature 生命科学11h ago
Summary
IL-6R blockade with tocilizumab disrupts pericyte– and tumor cell–driven IL-6/STAT3 signaling, enhancing docetaxel efficacy in ER+ breast cancer
We index headlines and summaries only. Full content and copyright remain with the original publisher — follow the source link to read it.
Open original- Desk
- Science
- Region
- Global
- Language
- English
- Item ID
- science-3aa545af
Comments 0 comments
No comments yet. Be the first.